Will IDXX's Q1 2025 earnings beat forecasts?

**IDXX's Q1 2025 earnings are likely to beat forecasts**, considering the company's historical performance, financial guidance, and recent news. Here's a detailed analysis: 1. **Financial Guidance**: IDEXX has provided financial guidance for Q1 2025, expecting revenue between $4.055 billion and $4.170 billion, with EPS ranging from $11.74 to $12.24. The consensus estimate for IDEXX's Q1 2025 revenue is $4.14 billion, which falls within the company's guidance range. 2. **Historical Performance**: IDEXX has a track record of solid growth, with full-year revenue reaching $3.898 billion in 2024, marking a 6% increase. The Companion Animal Group (CAG) Diagnostics recurring revenue grew by 7% organically, and the IDEXX VetLab® consumables saw a 12% revenue growth. 3. **Recent News**: IDEXX's fourth-quarter 2024 results exceeded expectations, with reported revenues of $954 million, a 6% increase year-over-year. The company's EPS for the quarter was $2.53, beating the consensus of $2.40. This recent performance indicates a strong possibility of meeting or exceeding earnings expectations in Q1 2025. 4. **Market Sentiment**: The overall market sentiment for IDEXX is positive, with analysts' estimates typically excluding special items. Additionally, the company's diversified business model, strong customer loyalty, and resilience in generating recurring revenues suggest a favorable outlook. In conclusion, considering IDEXX's financial guidance, historical performance, and recent news, it is reasonable to expect that the company's Q1 2025 earnings will likely beat forecasts.